{"url_path":"/sec/immx/8-k/2026-07-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-033829-index.html","accession_number":"0001493152-26-033829","cik":"0001873835","ticker":"IMMX","issuer_name":"Immix Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-033829-index.html","primary_entity_key":"0001873835","primary_entity_name":"Immix Biopharma, Inc."},"word_count":92,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n \n\nAs\nof July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the\nCompany. Given his short tenure, management believes there is no material effect on the business.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**Immix Biopharma, Inc.**\n\n \n \n\nDated:\nJuly 20, 2026\n*/s/\nIlya Rachman*\n\n \nIlya\nRachman, M.D., Ph.D.\n\n \nChief Executive Officer"}